Down-regulation of Skp2 is correlated with p27-associated cell cycle arrest induced by phenylacetate in human prostate cancer cells

Anticancer Research

Volumn 25, Issue 3 B, 2005, Pages 1881-1888

  Shibahara, Takuji ^a   Onishi, Takehisa ^a   Franco, Omar E ^a   Arima, Kiminobu ^a   Sugimura, Yoshiki ^a  

^a MIE UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

p27; Phenylacetate; Prostate cancer; Skp2

Indexed keywords

ANDROGEN; MESSENGER RNA; PHENYLACETIC ACID; PROTEIN KINASE B; PROTEIN P27; S PHASE KINASE ASSOCIATED PROTEIN 2;

ARTICLE; CANCER CELL CULTURE; CELL CYCLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DOWN REGULATION; DRUG MECHANISM; ENZYME INHIBITION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; REDUCTION; UBIQUITINATION; UPREGULATION;

ANTIBIOTICS, ANTINEOPLASTIC; CELL CYCLE; CELL CYCLE PROTEINS; CELL LINE, TUMOR; CYCLIN-DEPENDENT KINASE INHIBITOR P27; DOWN-REGULATION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; PHENYLACETATES; PROSTATIC NEOPLASMS; PROTEIN-SERINE-THREONINE KINASES; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-AKT; S-PHASE KINASE-ASSOCIATED PROTEINS; TRANSCRIPTION, GENETIC; TUMOR SUPPRESSOR PROTEINS; UBIQUITIN; UP-REGULATION;

EID: 21344459015     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (49)

1. Huggins C and Hodges CV: Studies on prostate cancer. I. The effect of castration, of estrogen, and androgen injection on serum phosphatases in metastatic carcinoma of the prostate. Cancer Res 1: 293, 1941.
2. Glitters RF: Carcinoma of the prostate. N Engl J Med 324: 235-245, 1991.
3. Sndler M, Ruthven CR, Goodwin BL, Lees A and Stern GM: Phenylacetic acid in human body fluids: high correlation between plasma and cerebrospinal fluid concentration values. J Neurol Neurosurg Psychiatry 45: 366-368, 1982.
4. Brusilow SW, Danney M, Waber LJ, Batshaw M, Burton B, Levitsky L, Roth K, McKeethren C and Ward J: Treatment of episodic hyperammonemia in children with inborn errors of urea synthesis. N Engl J Med 310: 1630-1634, 1984.
5. del Rosario M, Werlin SL and Lauer SJ: Hyperammonemic encephalopathy after chemotherapy. Survival after treatment with sodium benzoate and sodium phenylacetate. J Clin Gastroenterol 25: 682-684, 1997.
6. Samid D, Yeh A and Prasanna P: Induction of erythroid differentiation and fetal hemoglobin production in human leukemic cells treated with phenylacetate. Blood 80: 1576-1581, 1992.
7. Samid D, Shack S and Sherman LT: Phenlyacetate: a novel nontoxic inducer of tumor cell differentiation. Cancer Res 52: 1988-1992, 1992.
8. Samid D, Shack S and Myers CE: Selective growth arrest and phenotypic reversion of prostate cancer cells in vitro by nontoxic pharmacological concentrations of phenylacetate. J Clin Invest 91: 2288-2295, 1993.
9. Cinatl JJ, Cinatl J, Mainke M, Weibflog A, Rabenau H, Kornmhuber B and Doerr HW: In vitro differentiation of human neuroblastoma cells induced by sodium phenylacetate. Cancer Lett 70: 41-48, 1993.
10. Shack S, Miller A, Liu L, Prasanna P, Thibault A and Samid D: Vulnerability of multidrug-resistant tumor cells to the aromatic fatty acids phenylacetate and phenylbutyrate. Cancer Res 2: 865-872, 1996.
11. Gore SD, Samid D and Weng LJ: Impact of the putative differentiationing agents sodium phenylbutyrate and sodium phenylacetate on proliferation, differentiation and apoptosis of primary neoplastic myeloid cells. Clin Cancer Res 3: 1755-1762, 1997.
12. Omar E, Onishi T, Umeda Y, Soga N, Wakita T, Arima K, Yanagawa M and Sugimura Y: Phenylacetate inhibits growth and modulates cell cycle gene expression in renal cancer cell lines. Anticancer Res 23: 1637-1642, 2003.
13. Onishi T, Yamakawa K, Omar E, Suzuki R and Kawamura J: p27kip1 is the key mediator of phenylacetate induced cell cycle arrest in human prostate cancer cells. Anticancer Res 20: 3075-3082, 2000.
14. Yang RM, Naitoh J, Murphy M, Wang H-J, Phillipson J, DEKernion JB, Loda M and Reiter RE: Low p27 expression predicts poor disease-free survival in patients with prostate cancer. J Urol 159: 941-945, 1998.
15. Barnes A, Pinder SE, Bell JA, Paish EC, Wencyk PM, Robertson JFR, Elston CW and Ellis IO: Expression of p27kip1 in breast cancer and its prognotic significance. J Pathol 201: 451-459, 2003.
16. Filipits M, Pohl G, Stranzl T, Kaufmann H, Jutta A, Gisslinger H, Greinix H, Chott A and Drach J: Low p27kip1 expression is an independent adverse prognostic factor in patients with multiple myeloma. Clin Cancer Res 9: 820-826, 2003.
17. Nitti D, Belluco C, Mammano E, Marchet A, Ambrosi A, Mencarelli R, Segato P and Lise M: Low levels of p27kip1 protein expression in gastric adenocarcinoma is associated with disease progression and poor outcome. J Surg Oncol 81: 167-176, 2002.
18. Armengol C, Boix L, Bachs O, Sole M, Fuster J, Sala M, Llovet JM, Rodes J and Bruix J: p27kip1 is an independent predictor of recurrence after surgical resection in patients with small hepatocellular carcinoma. J Hepatol 38: 591-597, 2003.
19. Nakayama K-I, Hatakeyama S and Nakayama K: Regulation of the cell cycle at the G1-S transition by proteolysis of cyclin E and p27kip1. Biochem Biophys Res 282: 853-860, 2001.
20. Carrano AC, Eytan E, Hershko A and Pagano M: SKP2 is required for ubiquitin-mediated degradation of CDK inhibitor p27. Nature Cell Biol 1: 193-199, 1999.
21. Ganoth D, Bornstein G, Ko TK, Larsen B, Tyers M, Pagano M and Hershko A: The cell cycle regulatory protein Cks1 is required for SCFSkp2-mediated ubiquitinylation of p27. Nature Cell Biol 3: 321-324, 2001.
22. Medema RH, Kops GJ, Bos JL and Burgering BMT: AFX-like Forkhead transcription factors mediate cell-cycle regulation by Ras and PKB through p27kip1. Nature 404: 782-787, 2000.
23. Brunet A, Bonni A, Zigmond MJ, Lin MZ, Juo P, Hu LS, Anderson MJ, Arden KC, Blenis J and Greenberg M: Akt promotes cell survival by phosphorylating and inhibiting a Forkhead transcription factor. Cell 96: 857-858, 1999.
24. Kops GJ, Ruiter NDd, Vries-Smits AMd, Powell DR, Bos JL and Burgering BM: Direct control of the Forkhead transcription factor AFX by protein kinase B. Nature 398: 630-634, 1999.
25. Tang ED, Nunez G, Barr FG and Guan KL: Negative regulation of the Forkhead transcription factor FKHR by Akt. J Biol Chem 274: 16741-16746, 1999.
26. Takaishi H, Konishi H, Matsuzaki H, Ono Y, Shirai Y, Saiti N, Kitamura T, Ogawa W, Kasuga M, Kikkawa U and Nishizuka Y: Regulator of nuclear translocation of Forkhead transcription factor AFX by protein kinase B. Proc Natl Acad Sci USA 96: 11836-11841, 1999.
27. Hill MM and Hemmings BA: Inhibition of protein kinase B/Akt: implications for cancer thrapy. Pharmacol Ther 93: 243-251, 2002.
28. Nakatani K, Thompson DA, Barthel A, Sakaue H, Liu W, Weigel RJ and Roth RA: Up-regulation of Akt3 in estrogen receptor-deficient breast cancers and androgen-independent prostate cancer lines. J Biol Chem 274: 21528-21532, 1999.
29. Cheng JQ, Ruggeri B, Klein WM, Sonoda G, Altomare DA, Watson DK and Testa J: Amplication of AKT2 in human pancreatic cells and inhibition of AKT2 expression and tumorigenicity by antisense RNA. Proc Natl Acad Sci USA 93: 3636-3641, 1996.
30. Bellacosa A, Feo Dd, Godwin AK, Bell DW, Cheng JQ, Altomare DA, Wan M, Dubeau L, Scambia G, Masciullo V, Ferrandina G, Benedetti-Panici P, Mascuso S, Neri G and Testa J: Molecular alterations of the AKT2 oncogene in ovarian and breast carcinomas. Int J Cancer 64: 280-285, 1995.
31. Graff J, Konicek BW, McNulty AM, Wang Z, Houck K, Allen S, Paul JD, Hbaiu A, Goode RG, Sandusky GE, Vessella RL and Neubauer BL: Increased AKT activity contributes to prostate cancer progression by dramatically accelerating prostate tumor growth and diminishing p27kip1 expression. J Biol Chem 275: 24500-24505, 2000.
32. Crirns P, Okami K, Halachmi S, Halachmi N, Esteller M, Herman JG, Jen J, Isaacs WB, Bova GS and Sidransky D: Frequent inactivation of PTEN/MMAC1 in primary prostate cancer. Cancer Res 57: 4997-5000, 1997.
33. Suzuki H, Freije D, Nusskern DR, Okami K, Cairns P, Sidransky D, Isaacs WB and Bova GS: Interfocal heterogeneity of PTEN/MMAC1 gene alterations in multiple metastatic prostate cancer tissues. Cancer Res 57: 3660-3663, 1998.
34. Guldberg P, Straten Pt, Birck A, Ahrenkiel V, Lirkin AF and Zeuthen J: Disruption oh the MMAC1/PTEN gene by deletion or mutation is a frequent event in malignant melanoma. Cancer Res 57: 3660-3663, 1997.
35. Risinger JI, Hayes AK, Berchuck A and Barrett JC: PTEN/MMAC1 mutations in endometrial cancers. Cancer Res 57: 4736-4738, 1997.
36. Li J, Yen C, Liaw D, Podsypanina K, Bose S, Wang SI, Puc J, Miliaresis C, Rodgers L, McCombie R, Binger SH, Giovanella BC, Ittmann M, Tycko B, Hibshoosh H, Wigler MH and Parsons R: PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. Science 275: 1943-1947, 1997.
37. Persad S, Attwell S, Gray V, Delcommenne M, Troussard A, Sanghera J and Dedhar S: Inhibition of integrin-linked kinase (ILK) suppresses activation of protein kinase B/Akt and induces cell cycle arrest and apoptosis of PTEN-mutant prostate cancer cells. Proc Natl Acad Sci USA 97: 3207-3212, 2000.
38. Mamillapalli R, Gavrilova N, Mihaylova VT, Tsvetkov LM, Wu H, Zhang H and Sun H: PTEN regulates the ubiquitin-dependent degradation of the CDK inhibitor p27kip1 through the ubiquitin E3 ligase SCFskp2. Curr Biol 11: 263-267, 2001.
39. Saltiel AR and Olefsky JM: Thiazolidinediones in the treatment of insulin resistance and typeII diabetes. Diabetes 45: 1661-1669, 1996.
40. Lehmann JM, Moore LB, Smith-Oliver TA, Wilkinson WO, Wilson TM and Kliewer SA: An antidiabetic thiazoidinedione is a high affinity ligand for peroxisome proliferator-activated receptor g (PPARg). J Biol Chem 270: 12953-12956, 1995.
41. Mueller E, Sarraf P, Tontonoz P, Evans RM, Martin KJ, Zhang M, Fletcher C, Singer S and Spiegelman BM: Terminal differentiation of human breast cancer through PPARg. Mol Cell 1: 465-470, 1998.
42. Kubota T, Koshizuka K, Williamson EA, Asou H, Said JW, Holden S, Miyoshi I and Koeffler HP: Ligand for peroxisome proliferator-activated receptor γ (troglitazone) has potent antitumor effects against human prostate cancer both in vitro and in vivo. Cancer Res 58: 3344-3352, 1998.
43. Koga H, M.Harada, Ohtubo M, Shishido S, Kumemura H, Kanada S, Taniguchi E, Yamashita K, Kumashiro R, Ueno T and Sata M: Troglitazone induces p27kip1-associated cell-cycle arrest through down-regulating Skp2 in human hepatoma cells. Hepatology 37: 1086-1096, 2003.
44. Samid D, Wells M, Greene ME, Shen W, Palmer CAN and Thibault A: Peroxisome proliferator-activated receptor γ as a novel target in cancer therapy: binding and activation by an aromatic fatty acid with clinical antitumor activity. Clin Cancer Res 6: 933-941, 2000.
45. Han S, Wada RK and Sidell N: Differentiation of human neuroblastoma by phenylacetate is mediated by peroxisome proliferator-activated receptor γ. Cancer Res 61: 3998-4002, 2001.
46. Masuda TA, Inoue H, Sonoda H, Mine S, Yoshikawa Y, Nakayama K, Nakayama K and Mori M: Clinical and pathological significance of S-phase kinase-associated protein 2 (Skp2) gene expression in gastric carcinoma; modulation of malignant phenotype by Skp2 overexpression, possibly via p27 proteolysis. Cancer Res 62: 3819-3825, 2002.
47. Schiffer D, Cavalla P, Fiano V, Ghimenti C and Piva R: Inverse relationship between p27/Kip.1 and the F-box protein Skp2 in human astrocytic gliomas by immunohistochemistry and Western blot. Neurosci Lett 328: 125-128, 2002.
48. Ben-Izhak O, Lahav-Baratz S, Meretyk S, Ben-Eliezer S, Sabo E, Dirnfeld M, Cohen S and Ciechanover A: Inverse relationship between Skp2 ubiquitin ligase and the cyclin dependent kinase inhibitor p27kip1 in prostate cancer. J Urol 170: 241-245, 2003.
49. Shim EH, Johnson L, Noh HL, Kim YJ, Sun H, Zeiss C and Zhang H: Expession of the F-box protein SKP2 induces hyperplasia, dysplasia, and low-grade carcinoma in the mouse prostate. Cancer Res 63: 1583-1588, 2003.